Neoreviews
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
Vol. 2 No. 11, November 2001
Right arrow Author Disclosures
Right arrow E-Letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-Letters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wright, L. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Wright, L. L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

(NeoReviews. 2001;2:E257-e266.)
© 2001 American Academy of Pediatrics

The Role of Follow-up in Randomized Controlled Trials

Linda L. Wright, MD

*


* Center for Research for Mothers and Children, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD.


    Objectives
 
After completing this article, readers should be able to:

  1. Describe useful tools for interpreting the randomized controlled trial literature.
  2. Characterize the difference between a surrogate outcome and a clinically meaningful outcome.
  3. Characterize the trend in the prevalence of neurodevelopmental impairment in very low-birthweight infants.
  4. Describe the adverse effects that have been associated with postnatal steroid use and why they were first reported in 1998.
  5. Justify neurodevelopment or death as the outcome of randomized controlled trials of neonatal interventions.
  6. Describe the major methodologic problems in conducting such trials.


    Useful Tools
 
Dramatic increases in basic and translational research have increased the number of therapies available to clinicians. Because randomized clinical trials are the gold standard for evaluating the effect of treatment, there have been parallel increases in the number of randomized controlled trials (RCTs) and the refinement of methods for their design, conduct, analysis, and reporting. For investigators designing a clinical trial, clinicians seeking an answer to a specific clinical problem, and clinicians seeking to remain abreast of the trial literature, efficient access to and use of the medical literature is a major challenge. A number of tools have been developed for evaluating the effectiveness of new therapies, including systems to rate the quality of evidence, such as The United States Preventive Task Force’s rating system (Table 1Go ). (1)


View this table:
[in this window]
[in a new window]
 
Table 1. US Preventative Task Force’s Rating System

 
Another major advance is the development of standardized methods for formal, systematic reviews of trials of an intervention (meta-analysis). The Cochrane Collaboration, an organization committed to the preparation and dissemination of systematic reviews of health care interventions, uses such methods to identify high-quality trials and to obtain a summary estimate of the overall treatment effect of a specific intervention in a defined population on each outcome of interest. In addition to providing a typical estimate of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?





HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Academy of Pediatrics.